A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors
Status:
Terminated
Trial end date:
2020-05-04
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety of the study drug LY3381916 administered
alone or in combination with anti-programmed cell death ligand 1 (PD-L1) checkpoint antibody
(LY3300054).